Log in to search using one of your social media accounts:

 

Correction: Genetic Frontiers-Blindness-Gene Therapy story

Correction: Genetic Frontiers-Blindness-Gene Therapy story
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news

Related Links:

Abstract Leber's Optic Hereditary Neuropathy (LHON) is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 1871, the German ophthalmologist Theodor Leber was the first to describe the clinical characteristics of his namesake disease, and through unremitting efforts over the past 100 years, researchers have continued to increase their understanding of LHON. In recent years, using gene therapy, several groups have obtained breakthroughs in the treatment of the disease. In this article, we will review the challenging journey that researchers faced towards our curr...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research
LONDON (Reuters) - Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
(American Academy of Ophthalmology) Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 31 October 2017 Source:Progress in Retinal and Eye Research Author(s): Marina França Dias, Kwangsic Joo, Jessica A. Kemp, Silvia Ligório Fialho, Armando da Silva Cunha, Se Joon Woo, Young Jik Kwon Retinitis Pigmentosa (RP) is a hereditary retinopathy that affects about 2.5 million people worldwide. It is characterized with progressive loss of rods and cones and causes severe visual dysfunction and eventual blindness in bilateral eyes. In addition to more than 3000 genetic mutations from about 70 genes, a wide genetic overlap with other types of retinal dystrophies has been ...
Source: Progress in Retinal and Eye Research - Category: Opthalmology Source Type: research
3D printed digital contact lenses, bionic eye implants, augmented reality eye condition explainers: the future of vision and eye care are full of science fiction-sounding innovations. Here is where digital health will take ophthalmology in the future! More than 80 percent of perception comes through vision Researchers estimate that 80-85 percent of our perception, learning, cognition, and activities are mediated through vision. Compared to that, our hearing only processes 11 percent of information, while smell 3.5 percent, touch 1.5 percent and taste 1 percent. Don’t you think that’s possible? Renowne...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Augmentation in Medicine Cyborgization Medical Augmented Reality 3d printing AI diabetes digital digital health eye care future guide Healthcare Innovation ophthalmology Personalized medicine technology vision Source Type: blogs
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news
Publication date: Available online 16 October 2017 Source:Progress in Retinal and Eye Research Author(s): Dimitra Athanasiou, Monica Aguila, James Bellingham, Wenwen Li, Caroline McCulley, Philip J. Reeves, Michael E. Cheetham Inherited mutations in the rod visual pigment, rhodopsin, cause the degenerative blinding condition, retinitis pigmentosa (RP). Over 150 different mutations in rhodopsin have been identified and, collectively, they are the most common cause of autosomal dominant RP (adRP). Mutations in rhodopsin are also associated with dominant congenital stationary night blindness (adCSNB) and, less frequently, re...
Source: Progress in Retinal and Eye Research - Category: Opthalmology Source Type: research
An experimental gene therapy for a rare hereditary form of blindness is a step closer to reality. An FDA advisory panel voted unanimously Thursday to recommend approval of a groundbreaking treatment for people with a faulty gene that impairs vision. It would be the first gene therapy in the U.S. for an inherited disease. Dr. David Agus joins "CBS This Morning" to discuss how the treatment works and why it could be a new frontier in treating genetic disorders.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
The FDA advisory committee gave a unanimous thumbs-up to gene therapy for one form of inherited blindness, paving the way for others.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news
If approved, it would be the first gene therapy in the U.S. for an inherited disease
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
More News: Blindness | Gene Therapy | Genetics | Health | Opthalmology